COVID-19 during Early Phase of Autologous Stem Cell Transplantation

Abstract

We present one of few cases of COVID-19 occurrence during the early phase of autologous hematopoietic stem cell transplantation. We observed an interesting correlation between the patient’s rapid clinical deterioration and myeloid reconstitution that cannot be assigned to engraftment syndrome. Our report emphasizes the need to investigate whether timely steroid therapy upon neutrophil engraftment in the setting of COVID-19 could limit the extent of lung injury and prevent ARDS. Furthermore, we discuss a significant issue of possible prolonged incubation of the virus in heavily pretreated hematological patients.

COVID‐19 does not impact on outcome of myeloma patients infected while undergoing autologous stem cell transplantation

“…Therefore, even if many data have been collected about the prognosis of ASCT recipients who developed SARS‐Cov‐2 infection after the treatment, few cases are reported about HM patients undergoing ASCT during Sars‐Cov‐2 infection, 5,6 suggesting the possibility of a favorable ASCT outcome. Here we report two myeloma patients with SARS‐Cov‐2 infection developed during ASCT.…”